Method of treating fibroblast growth factor 21 (FGF-21) deficiency
US10874714B2 · kind B2 · utility
1Cited by
208References
8Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Nov 30, 2015 |
| Grant date | Dec 29, 2020 |
| Priority date | — |
| Expiry date | Nov 9, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to mutants of Fibroblast Growth Factor (FGF), particularly FGF-20 and FGF-21, which contain newly introduced N-linked or O-linked glycosylation site(s). The polynucleotide coding sequences for the mutants, expression cassettes comprising the coding sequences, cells expressing the mutants, and methods for producing the mutants are also disclosed. Further disclosed are pharmaceutical compositions comprising the mutants and method for using the mutants.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.